By transcriptome sequencing of clinical glioma samples of p53 mutants (19NS, 84NS, 157NS, and 528NS), the results showed that p53 mutants could promote the upregulation of inflammatory factor CCL2 and chemotactic gene tumor necrosis factor-α expression in glioma (Ham et al., 2019). The gene discussed is TP53; the disease is glioma.